Stock Events

Stock Events

Protalix BioTherapeutics 

€1.83
0
-€0.02-0.98% Monday 06:03

Statistics

Day High
1.83
Day Low
1.83
52W High
2.66
52W Low
1.19
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q4 2025
Next
-0.05
-0.02
0.01
0.03
Expected EPS
-0.0085339
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBDA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes in the biopharmaceutical space, developing drugs that could directly compete with Protalix's treatments.
AMGEN
AMGN
Mkt Cap178B
Amgen focuses on novel therapies in various areas, including those that Protalix targets, making them direct competitors.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences operates in the biopharmaceutical field, producing competitive drugs in the same therapeutic areas as Protalix.
Biogen
BIIB
Mkt Cap27.62B
Biogen develops therapies for diseases with unmet medical needs, potentially competing with Protalix's product pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is involved in creating treatments for serious diseases, some of which may overlap with Protalix's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals develops biologic medicines, including for conditions that Protalix is also targeting.
Novo Nordisk
NVO
Mkt Cap194.57B
Novo Nordisk is a global healthcare company with products that could compete in the therapeutic areas Protalix is involved in.
Sanofi
SNY
Mkt Cap110.4B
Sanofi develops a wide range of medicines, including those in areas where Protalix is seeking to make an impact.

About

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Show more...
CEO
Mr. Dror Bashan
Employees
213
Country
United States
ISIN
US74365A3095

Listings

STU
DE
PBDA.STU
MU
DE
PBDA.MU
XASE
US
PLX
F
DE
PBDA.F

0 Comments

Share your thoughts

FAQ

What is Protalix BioTherapeutics stock price today?▼
The current price of PBDA.MU is €1.83 EUR — it has decreased by -0.98% in the past 24 hours. Watch Protalix BioTherapeutics stock price performance more closely on the chart.
What is Protalix BioTherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Protalix BioTherapeutics stocks are traded under the ticker PBDA.MU.
Is Protalix BioTherapeutics stock price growing?▼
PBDA.MU stock has fallen by -1.83% compared to the previous week, the month change is a -0.11% fall, over the last year Protalix BioTherapeutics has showed a -28.03% decrease.
When is the next Protalix BioTherapeutics earnings date?▼
Protalix BioTherapeutics is going to release the next earnings report on May 08, 2026.
What were Protalix BioTherapeutics earnings last quarter?▼
PBDA.MU earnings for the last quarter are -0.05 EUR per share, whereas the estimation was 0.03 EUR resulting in a -250% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Protalix BioTherapeutics have?▼
As of May 06, 2026, the company has 213 employees.
In which sector is Protalix BioTherapeutics located?▼
Protalix BioTherapeutics operates in the Health & Wellness sector.
When did Protalix BioTherapeutics complete a stock split?▼
Protalix BioTherapeutics has not had any recent stock splits.
Where is Protalix BioTherapeutics headquartered?▼
Protalix BioTherapeutics is headquartered in Hackensack, United States.